
The groundbreaking study utilized Mendelian randomization (MR) to explore the causal link between amino acid levels and the risk of metabolic dysfunction-associated fatty liver disease (MAFLD). Analyzing data from large genome-wide association studies revealed that genetically predicted elevated alanine and reduced glutamine levels are associated with a higher MAFLD risk. The findings, supported by sensitivity analyses, suggest potential metabolite targets for MAFLD prevention or treatment, significantly advancing the understanding of the disease's etiology.
Like
Save
Share